- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02695420
Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
July 25, 2021 updated by: Cytokinetics
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
- To evaluate pharmacokinetics (PK) of omecamtiv mecarbil in Japanese subjects with heart failure (HF) with reduced ejection fraction
- To evaluate the safety and tolerability of oral omecamtiv mecarbil
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator.
Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.
Study Type
Interventional
Enrollment (Actual)
81
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Aichi
-
Kasugai-shi, Aichi, Japan, 486-8510
- Research Site
-
Kasugai-shi, Aichi, Japan, 487-0016
- Research Site
-
Nagoya-shi, Aichi, Japan, 454-8509
- Research Site
-
-
Chiba
-
Asahi-shi, Chiba, Japan, 289-2511
- Research Site
-
Chiba-shi, Chiba, Japan, 260-8606
- Research Site
-
-
Ehime
-
Imabari-shi, Ehime, Japan, 799-1592
- Research Site
-
-
Fukuoka
-
Chikushino-shi, Fukuoka, Japan, 818-8516
- Research Site
-
Fukuoka-shi, Fukuoka, Japan, 814-0180
- Research Site
-
Fukuoka-shi, Fukuoka, Japan, 815-8588
- Research Site
-
-
Hokkaido
-
Hakodate-shi, Hokkaido, Japan, 041-8512
- Research Site
-
Sapporo, Hokkaido, Japan, 060-8648
- Research Site
-
-
Hyogo
-
Amagasaki-shi, Hyogo, Japan, 660-8550
- Research Site
-
Kawanishi-shi, Hyogo, Japan, 666-0125
- Research Site
-
Takarazuka-shi, Hyogo, Japan, 665-0873
- Research Site
-
-
Ishikawa
-
Kanazawa-shi, Ishikawa, Japan, 920-8650
- Research Site
-
-
Kochi
-
Nankoku-shi, Kochi, Japan, 783-8505
- Research Site
-
-
Oita
-
Oita-shi, Oita, Japan, 870-0192
- Research Site
-
-
Okayama
-
Okayama-shi, Okayama, Japan, 702-8055
- Research Site
-
-
Osaka
-
Kishiwada-shi, Osaka, Japan, 596-8522
- Research Site
-
Osaka-shi, Osaka, Japan, 532-0003
- Research Site
-
Osaka-shi, Osaka, Japan, 550-0012
- Research Site
-
Osaka-shi, Osaka, Japan, 559-0012
- Research Site
-
Suita-shi, Osaka, Japan, 565-0871
- Research Site
-
-
Saga
-
Saga-shi, Saga, Japan, 840-8571
- Research Site
-
-
Saitama
-
Saitama-shi, Saitama, Japan, 330-8503
- Research Site
-
Wako-shi, Saitama, Japan, 351-0102
- Research Site
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japan, 411-8611
- Research Site
-
-
Tokyo
-
Chiyoda-ku, Tokyo, Japan, 101-8309
- Research Site
-
Itabashi-ku, Tokyo, Japan, 173-0015
- Research Site
-
Itabashi-ku, Tokyo, Japan, 173-8610
- Research Site
-
Meguro-ku, Tokyo, Japan, 152-8902
- Research Site
-
Shinagawa-ku, Tokyo, Japan, 141-0001
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Japanese male or female ≥ 20 years and ≤ 85 years of age
- History of chronic stable heart failure (HF) with reduced ejection fraction, defined as requiring treatment for HF for a minimum of 4 weeks prior to screening
- Treated for HF with optimal pharmacological therapy
- Left ventricular ejection fraction ≤ 40% at screening
Exclusion Criteria:
- Severe uncorrected valvular heart disease
- Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically significant congenital heart disease
- Acute myocardial infarction, unstable angina, or persistent angina at rest within 30 days prior to randomization
- Systolic blood pressure (BP) > 160 mmHg or < 90 mmHg, or diastolic BP > 90 mmHg, or heart rate (HR) > 110 beats per minute (bpm) or HR < 50 bpm
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2
- Total bilirubin (TBL) ≥ 2x upper limit of normal (ULN), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3x ULN Other Exclusion Criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo BID
Participants will receive placebo BID.
|
oral tablet
|
Experimental: 25 mg Omecamtiv Mecarbil BID
Participants will receive 25 mg omecamtiv mecarbil BID.
|
oral tablet
|
Experimental: 37.5 mg Omecamtiv Mecarbil BID Target Dose
Participants will receive omecamtiv mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 37.5 mg BID after Week 4 or Week 8, based on Week 2 PK.
|
oral tablet
oral tablet
|
Experimental: 50 mg Omecamtiv Mecarbil BID Target Dose
Participants will receive Omecamtiv Mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 50 mg BID after Week 4 or Week 8, based on Week 2 PK.
|
oral tablet
oral tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time
Time Frame: Before morning dose on Week 2 (Day 15), Week 4 (Day 28), Week 12 (Day 84), Week 16 (Day 112)
|
Before morning dose on Week 2 (Day 15), Week 4 (Day 28), Week 12 (Day 84), Week 16 (Day 112)
|
PK: Area Under the Curve Until 8 Hours After Morning Dose at Week 8 (AUC0-8)
Time Frame: Week 8 (Day 56) at predose, at 2 hours ±30 minutes; 4 hours ±30 minutes; 6 hours ±30 minutes; 8 hours ±30 minutes after morning dose
|
Week 8 (Day 56) at predose, at 2 hours ±30 minutes; 4 hours ±30 minutes; 6 hours ±30 minutes; 8 hours ±30 minutes after morning dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline at Week 16 in Systolic Ejection Time (SET)
Time Frame: Baseline, Week 16 (Day 112)
|
LS mean was from the repeated measures model, which included treatment group, stratification factor (from IVRS), scheduled visit, baseline value, and the interaction of treatment group with scheduled visit as covariates.
|
Baseline, Week 16 (Day 112)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time Frame: From first dose of study drug up to Week 20 (Day 140 + 3 days)
|
An adverse event (AE) is defined as any untoward medical occurrence.
Serious AEs are defined as AEs that meets at least 1 of the following serious criteria: fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, other medically important serious event.
AEs are graded as: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death.
TEAEs are defined as events occurring after the first dose of study drug.
|
From first dose of study drug up to Week 20 (Day 140 + 3 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 14, 2016
Primary Completion (Actual)
April 6, 2017
Study Completion (Actual)
May 8, 2017
Study Registration Dates
First Submitted
February 25, 2016
First Submitted That Met QC Criteria
February 25, 2016
First Posted (Estimate)
March 1, 2016
Study Record Updates
Last Update Posted (Actual)
July 27, 2021
Last Update Submitted That Met QC Criteria
July 25, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20120227
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure With Reduced Ejection Fraction
-
Novartis PharmaceuticalsCompletedHeart Failure With Reduced Ejection Fraction (HFrEF) | or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)Netherlands, United States
-
University of SienaEuropean Association of Cardiovascular ImagingActive, not recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection FractionSpain, Greece, Turkey, Portugal, Australia, Belgium, Italy, Mexico, Netherlands, North Macedonia, Romania, Tunisia
-
University Hospital, AkershusNovartisActive, not recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionNorway
-
Milton S. Hershey Medical CenterWithdrawnHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Board of Trustees of Illinois State UniversityUniversity of Colorado, Denver; Abbott; University of North Carolina, Greensboro and other collaboratorsRecruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Medical University of South CarolinaCompletedHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Normal Ejection FractionUnited States
-
Milton S. Hershey Medical CenterCompletedHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Massachusetts General HospitalRoche DiagnosticsRecruitingCardiovascular Risk Factor | Heart Failure With Reduced Ejection Fraction | Heart Failure With Normal Ejection Fraction | Heart Failure, Right Sided | Heart Failure With Mid Range Ejection FractionUnited States
-
Occlutech International ABActive, not recruitingHeart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure With Reduced Ejection Fraction (HFrEF)United States
-
Fondazione Toscana Gabriele MonasterioAzienda Ospedaliera Città della Salute e della Scienza di TorinoNot yet recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Midrange Ejection FractionItaly
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States